Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Dr Wang on the Role of Bridging Radiotherapy Prior to CAR T-Cell Therapy in B-Cell Lymphoma

October 16th 2025

Pule Wang, MD, discusses CNS bridging radiotherapy prior to CAR T-cell therapy in B-cell lymphomas.

FDA Approval Insights: Subcutaneous Pembrolizumab for Solid Tumors: With J. Thaddeus Beck, MD, FACP

October 16th 2025

J. Thaddeus Beck, MD, FACP, about the FDA approval of subcutaneous pembrolizumab.

Teclistamab Plus Daratumumab Boosts Survival in R/R Myeloma

October 16th 2025

Teclistamab plus daratumumab improved progression-free and overall survival in relapsed/refractory multiple myeloma after 1 to 3 lines of therapy.

Pembrolizumab Plus Chemo With or Without Bevacizumab Improves OS in Platinum-Resistant Ovarian Cancer

October 16th 2025

Pembrolizumab plus chemotherapy with or without bevacizumab improved overall survival in platinum-resistant ovarian cancer.

Toripalimab Plus CCRT Generates 100% ORR, But Safety Concerns Warrant Additional Research in Locally Advanced Cervical Cancer

October 16th 2025

Toripalimab plus CCRT produced a 100% ORR in locally advanced cervical cancer, although the regimen was associated with radiation-related AEs and irAEs.

Dr Gupta on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

October 15th 2025

Shilpa Gupta, MD, discusses the clinical effects of findings from the phase 3 EV-302/KEYNOTE-A39 trial in locally advanced/metastatic urothelial carcinoma.

Dr Le on the Efficacy of Firmonertinib for the Treatment of EGFR PACC–Mutated NSCLC

October 15th 2025

Xiuning Le, MD, PhD, discusses efficacy data with firmonertinib for the treatment of patients with EGFR PACC–mutated NSCLC.

Dr Lou on the Rationale for Evaluating CISH Knockout TILs Using CRISPR-Cas9 Gene Editing in Metastatic GI Cancers

October 15th 2025

Emil Lou, MD, PhD, FACP, discusses the rationale for evaluating CISH knockout TILs using CRISPR-Cas9 gene editing in metastatic GI cancers.

Dr Saad on Baseline Patient Characteristics From the Phase 3 PEACE-3 Trial in mCRPC

October 15th 2025

[The baseline patient population] represents what we see in the real world, with a median age of 73. [This] is older than what we see in [many] clinical trials.

Dr Dreyling on Prior Findings From the ECHO Trial of Acalabrutinib Plus BR in Pretreated MCL

October 15th 2025

Martin Dreyling, MD, discusses prior findings and potential implications of the phase 3 ECHO trial of acalabrutinib plus BR in pretreated MCL.

FDA Approval of TAR-200 Represents Potential Bladder-Sparing Option in BCG-Unresponsive NMIBC

October 15th 2025

Joseph Jacob, MD, MCR, discusses the significance of the FDA approval of TAR-200 for BCG-unresponsive non–muscle-invasive bladder cancer.

Baseline Cardiovascular Assessment, Monitoring Are Crucial With BTK Inhibitors in CLL and Other Hematologic Malignancies

October 14th 2025

A meta analysis found BTK inhibitors carry risks of hypertension, atrial fibrillation, and hemorrhage, underscoring the need for cardiovascular monitoring.

Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress

October 13th 2025

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

Olaparib Withstands the Test of Time With Long-Term Data Supporting Its Role in Ovarian Cancer Treatment

October 13th 2025

Kevin Elias, MD, discusses the role of olaparib in the management of ovarian cancer.

Dr Sweis on the Mechanism of Action of XmAb819 in RCC

October 10th 2025

Randy F. Sweis, MD, explains the mechanism of action of the ENPP3/CD3–targeted bispecific T-cell engager XmAb819 in renal cell carcinoma.

Removal of REMS Requirements Could Help Streamline CAR T-Cell Therapy Access in Hematologic Cancer Care

October 10th 2025

The removal of REMS programs for approved CAR T-cell therapies could enable improved access and streamlined management of hematologic malignancies.

Dr Elias on Efficacy Data With Olaparib in BRCA-Mutated Ovarian Cancer

October 10th 2025

Kevin Elias, MD, discusses the SOLO-1 and SOLO-2 trials, which evaluated olaparib in newly diagnosed and relapsed BRCA-mutated ovarian cancer.

Ibrutinib Plus Rituximab Shows PFS Benefit Over Chemoimmunotherapy in Untreated MCL

October 10th 2025

Ibrutinib plus rituximab showed a progression-free survival benefit vs standard chemoimmunotherapy in older patients with untreated mantle cell lymphoma.

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Diagnosed Myeloma

October 9th 2025

Daratumumab plus lenalidomide, with reduced exposure to dexamethasone, led to a PFS improvement in frail, newly diagnosed multiple myeloma.

ONO-4578 Plus Nivolumab/Chemo Improves PFS in HER2– Advanced Gastric Cancer

October 9th 2025

ONO-4578 plus nivolumab and chemotherapy improved PFS in HER2-negative advanced gastric cancer.